Adipotide Peptide Research
Adipotide is an investigational peptidomimetic designed to home to white-fat vasculature and trigger apoptosis in adipose blood vessels.
metabolic peptide
Preclinical
research maturity
Overview
Adipotide is an investigational peptidomimetic designed to home to white-fat vasculature and trigger apoptosis in adipose blood vessels. It has not been approved for routine clinical use, and the best-known efficacy data come from animal and primate work rather than modern human obesity trials.
Related stacks
Advanced Metabolic Stack
Metabolic Stack
Mechanism
Adipotide links an adipose-vasculature homing sequence to a pro-apoptotic motif. The proposed effect is reduction of fat mass by damaging the blood supply to white adipose tissue rather than by suppressing appetite, slowing gastric emptying, or directly activating incretin pathways.
Clinical interest
Clinical interest centers on obesity biology, adipose-tissue remodeling, and targeted metabolic research. It is more accurate to frame adipotide as an experimental fat-biology compound than as an established obesity therapy.
Research summary
The foundational translational signal comes from obese primate work showing weight loss and metabolic improvement, supported by broader vascular-targeting reviews. By comparison with semaglutide, tirzepatide, or retatrutide, the evidence base remains preclinical and far less mature.
Safety considerations
Renal tubular injury has been the leading toxicity concern in animal development work, with dose-related kidney effects being the main translational barrier. Human dosing, durability, and off-target vascular safety remain inadequately characterized.
Key information
Research stage
Preclinical
Evidence rating
Low
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
6
)
Frequently asked questions
What is adipotide?
Adipotide is a vascular-targeting peptidomimetic built to selectively impair blood supply to fat tissue rather than acting through GLP-1, GIP, or growth-hormone pathways.
Is adipotide supported by human trials?
Not in a way that supports routine clinical use. The best-known efficacy signal remains preclinical, especially in obese primate models, without an approved-drug level human program.